Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Share
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Mike Mayo, Wells Fargo analyst, joins ‘Closing Bell: Overtime’ to discuss why he raised his price target on Citigroup to $70 dollars. 04:27 Tue, May 17 20224:43 PM EDT
House Financial Services Committee vice chairman and Digital Assets Committee chairman Rep. French Hill (R-Ark.) joins ‘Squawk Box’ to discuss the SEC’s approval of spot bitcoin ETFs, what it means for crypto regulation in Congress, and more.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Morgan Brennan joins ‘Power Lunch’ to report on Goldman Sachs’ sweeping downgrade of key stocks in the defense sector. 03:57 Fri, Jan 13 20232:43 PM EST
© 2024 CNBC LLC. All Rights Reserved. A Division of NBCUniversal Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Market Data Terms of Use and Disclaimers Data also provided by
CNBC’s John Harwood asks Harry Reid about his boxing days.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Investors seem to be expecting a “massive” stimulus from the Democratic sweep of Congress, according to Jim Lowell, CIO of Adviser Investments. 00:00 Fri, Jan 8 20212:43 AM EST